With support from the Australian Melanoma Research Foundation in 2021, Dr Rebecca Simpson explored a fascinating and emerging area of cancer research: the connection between diet, gut health and immunotherapy outcomes.
Her work formed part of a major international collaboration involving researchers and patients from Australia, the Netherlands and the United States. Published in Nature Medicine, the study investigated whether the trillions of microorganisms living in our digestive system, collectively known as the gut microbiome, could influence how effectively a patient’s immune system responds to cancer treatment.
“Overall, our data demonstrate a path to optimizing the utility of the microbiome in the clinic and development of more targeted interventions to reshape the microbiome and improve treatment outcomes”
The research revealed that patients whose gut microbiomes were rich in beneficial bacteria were significantly more likely to respond to immunotherapy. These patients also appeared less likely to experience severe treatment-related side effects.
One of the most striking findings was the role of nutrition. Patients with diets higher in fibre and omega-3 fatty acids were more likely to have the types of gut microbiomes associated with positive treatment responses. Researchers also observed lower levels of inflammation in these patients before treatment commenced, suggesting that dietary habits may help shape the body’s readiness to respond to immunotherapy.
The study found that microbiomes dominated by bacteria associated with fibre-rich diets were linked to stronger treatment responses across multiple countries and patient groups. This suggests that lifestyle factors may play a much larger role in cancer treatment outcomes than previously understood.
While researchers caution that dietary changes alone are not a substitute for medical treatment, the findings provide compelling evidence that nutrition, gut health and the immune system are closely interconnected. The work opens the door to future studies investigating whether personalised nutrition plans or microbiome-targeted interventions could improve outcomes for people receiving immunotherapy.
For melanoma patients, this research offers an exciting glimpse into a future where treatment may be tailored not only to a person’s tumour, but also to their unique biology, lifestyle and gut health.
Thanks to AMRF’s support of innovative researchers like Dr Simpson, discoveries such as these are helping pave the way towards more personalised, effective and patient-centred melanoma care.
